WEBULL

Top Penny Stocks To Watch In September 2025

Simply Wall St · 09/04/2025 11:05

As of early September 2025, the U.S. stock markets have shown resilience, with major indices like the S&P 500 and Nasdaq climbing higher, driven by gains in big tech stocks and declining Treasury yields following soft jobs data. For investors exploring opportunities beyond large-cap stocks, penny stocks remain an intriguing option despite their somewhat outdated moniker. These stocks often represent smaller or newer companies that can offer significant growth potential when backed by strong financials and solid fundamentals.

Top 10 Penny Stocks In The United States

Name Share Price Market Cap Rewards & Risks
Dingdong (Cayman) (DDL) $2.07 $454.33M ✅ 4 ⚠️ 0 View Analysis >
Waterdrop (WDH) $1.78 $636.53M ✅ 4 ⚠️ 0 View Analysis >
WM Technology (MAPS) $1.14 $194.96M ✅ 4 ⚠️ 2 View Analysis >
Performance Shipping (PSHG) $1.84 $22.75M ✅ 4 ⚠️ 2 View Analysis >
Table Trac (TBTC) $4.95 $22.7M ✅ 2 ⚠️ 2 View Analysis >
Riverview Bancorp (RVSB) $4.83 $103.28M ✅ 2 ⚠️ 1 View Analysis >
BAB (BABB) $0.9101 $6.97M ✅ 2 ⚠️ 3 View Analysis >
Lifetime Brands (LCUT) $4.10 $95.16M ✅ 3 ⚠️ 3 View Analysis >
North European Oil Royalty Trust (NRT) $5.00 $46.78M ✅ 2 ⚠️ 2 View Analysis >
TETRA Technologies (TTI) $4.72 $634.41M ✅ 3 ⚠️ 2 View Analysis >

Click here to see the full list of 378 stocks from our US Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

MacroGenics (MGNX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing antibody-based cancer therapeutics in the United States with a market cap of approximately $109.98 million.

Operations: The company generates $165.50 million from its activities in developing and commercializing monoclonal antibody-based therapeutics.

Market Cap: $109.98M

MacroGenics, Inc. has shown revenue growth with US$22.24 million reported in Q2 2025, up from US$10.8 million the previous year, while reducing its net loss to US$36.25 million from US$55.66 million a year ago. Despite being dropped from several Russell indices and facing high volatility in its share price, the company maintains a strong cash position with short-term assets of US$204.9M exceeding liabilities and has secured non-dilutive capital through strategic agreements like the royalty purchase deal for ZYNYZ. Leadership changes include Eric Risser's appointment as CEO, reflecting ongoing strategic shifts within the firm.

MGNX Debt to Equity History and Analysis as at Sep 2025
MGNX Debt to Equity History and Analysis as at Sep 2025

Shattuck Labs (STTK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Shattuck Labs, Inc. is a biotechnology company focused on developing antibodies for treating inflammatory and immune-mediated diseases, with a market cap of $48.38 million.

Operations: Shattuck Labs currently does not report any revenue segments.

Market Cap: $48.38M

Shattuck Labs, Inc., a biotechnology firm with a market cap of US$48.38 million, remains pre-revenue with no significant income streams. Recent developments include the FDA's acceptance of its IND application for SL-325, an innovative antibody targeting inflammatory bowel disease. The company has secured US$45.67 million through a private placement to fund ongoing research and development efforts. Despite high volatility in its share price and continued unprofitability, Shattuck's short-term assets exceed liabilities significantly, providing some financial stability. Leadership changes have occurred with new board appointments following several resignations in August 2025.

STTK Revenue & Expenses Breakdown as at Sep 2025
STTK Revenue & Expenses Breakdown as at Sep 2025

Qudian (QD)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Qudian Inc. is a consumer-oriented technology company in China with a market cap of approximately $769.49 million.

Operations: The company generates revenue primarily from its Installment Credit Services, amounting to CN¥136.53 million.

Market Cap: $769.49M

Qudian Inc., a consumer-oriented technology company, has recently completed a significant share buyback program, repurchasing 12.79% of its shares for $54.6 million. Despite reporting sharply lower revenues of CN¥3.49 million for the first half of 2025 compared to the previous year, Qudian achieved net income growth to CN¥311.76 million, indicating profitability improvements. The company's financial health is bolstered by short-term assets exceeding both short and long-term liabilities significantly, while its debt-to-equity ratio has improved over five years from 13% to 6.2%. However, negative operating cash flow suggests challenges in covering debt obligations through cash generation alone.

QD Financial Position Analysis as at Sep 2025
QD Financial Position Analysis as at Sep 2025

Summing It All Up

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.